The Press Release
Partnership agreement signed with the International Medical Center in Saudi Arabia to provide OncoDNA’s full range of diagnostic products
Marks the Company’s first direct hospital deal in the Middle East
Continued success of highly scalable business model
OncoDNA (“OncoDNA” or “the Company”), the healthcare technology company making precision medicine a reality, announces today that it has signed an agreement with the world-class International Medical Center (“IMC”) in Jeddah, Saudi Arabia.
The state-of-the-art IMC facility in Saudi Arabia will provide the full range of OncoDNA’s genetic and molecular testing products: OncoDEEP, OncoSELECT, OncoSTRAT&GO and OncoTRACE. These tests combine advanced, comprehensive testing of cancer biomarkers with a proprietary cancer treatment knowledge database that enables oncologists to identify which of the latest cancer therapies available today are most suitable for their patients.
The partnership, OncoDNA’s first hospital agreement in the region, will enable IMC oncologists to select precision medicine treatments for patients which would otherwise not be identified through routine testing.
Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said:
“We are delighted to announce this partnership agreement for our molecular profiling services with the IMC in Saudi Arabia, an outstanding and ambitious facility that offers its patients the very latest advances in oncology care. The agreement marks the initial expansion of our services in the Middle East, and we are pleased that our precision medicine products continue to receive ever-greater recognition from leading oncology practitioners and centers across the world. OncoDNA’s revenue-generating and highly scalable model continues to develop at pace, supporting the treatment of cancer with precision medicine across the globe.”
Dr. Ahmed A Refae MD, of the Oncology Department at the IMC, said:
“This agreement helps us to offer our patients the most comprehensive molecular and genomic testing available today. OncoDNA’s diagnostic and precision medicine services provide the comprehensive sequencing and assessment of genetic mutations and enzymes before analysing this data and offering the most suitable and targeted biological and chemotherapeutic options.“
Dr Ibrahim Mansoor, Chairman Pathology & Lab Med & Blood Bank at IMC said:
“As a state-of-the-art facility, the IMC strives to provide the best possible diagnostic services and treatments, and OncoDNA’s diagnostic and precision medicine tools will help our oncology division to do so, allowing our patients to access the highest possible standard of care. We are excited by the prospect of offering the most innovative diagnostic support available to new and existing patients in Jeddah and elsewhere, providing both significant clinical benefits and cost savings.”
About OncoDEEP, OncoSELECT, OncoSTRAT&GO and OncoTRACE
OncoDEEP was the first solution developed by OncoDNA in 2013. It profiles solid tumor by sequencing an extensive variety of genes linked to approved targeted therapies, combined with IHC tests to detect important proteins and with other tests, such as MSI, gene fusion or promoter methylation. The NGS panel is based on an accurate analysis of oncologists’ needs in their current practice when the choice of solutions is reduced for the patients. The panel is updated every year based on advances reported in the literature, so as to provide patients with the most economical effective solutions. OncoDEEP provides information about approved or in development hormonal therapies, immunotherapies (through a personalised immunogram) and chemotherapies, as well as targeted therapies.
OncoSELECT is a fast, minimally invasive analysis of circulating tumour DNA from a blood sample for metastatic lung (NSCLC), colon and breast (ER+ or HER2+) cancer patients. It is the perfect tool to identify therapeutic solutions (approved targeted therapies) for cancer patients not able to get their tumour biopsied (or too old biopsy), to monitor the progression of their cancer and to detect treatment resistance as soon as it appears.
OncoSTRAT&GO combines the analysis of a solid biopsy sample (from the primary tumour or a metastasis) and the analysis of a liquid biopsy (from a blood sample). Analysis of the solid tumour includes the sequencing of 193 genes linked to approved or in development targeted therapies. This gene panel is based on the one used for the NCI-MATCH trial and was first selected for its scientific relevance: important pathways, signalling cascades, tumour metabolism, apoptosis, growth factors and DNA repair. After the first validation process, we improved the panel to cover some missing regions, added extra genes and compensated for some issues with the robustness of some amplicons due to the quality of the DNA. Additionally, we combine sequencing with IHCs and other tests, such as MSI, gene fusion or promoter methylation. This combination provides information about approved or in development hormonal therapies, immunotherapies (through a personalised immunogram) and chemotherapies, as well as targeted therapies. The analysis of the liquid biopsy gives insight into tumour heterogeneity by sequencing 40 genes linked to targeted therapies.
OncoTRACE is a test based on circulating tumour DNA (ctDNA) in liquid biopsies. It is used to monitor the progression of the tumour (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customised for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.
About International Medical Center Saudi Arabia
The International Medical Center is a multi-disciplinary hospital that features specialty centers providing a wide range of comprehensive treatment options for different health problems. These services are delivered by more than 150 US, Canadian and European certified physicians in more than thirty specialties including Orthopedics, Cardiology, Oncology, Women’s Health and Children’s Health. The hospital is equipped with state-of-the-art facilities that enable it to rank among the best healthcare providers in the region.
International Medical Center was the first hospital in Kingdom of Saudi Arabia to join the Mayo Clinic Care Network, a group of carefully vetted, independent health systems that have special access to Mayo Clinic’s knowledge and expertise to better serve patients and their families.
|OncoDNA||+32 (0) 71 18 35 00|
|Jean-Pol Detiffe, CEO|
|Pierre Flamant, CFO|
|Consilium Strategic Communications||+44 (0)20 3709 5700|
|Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thysemail@example.com|